Whalesbook
EQT Stands Alone Amid Deal Valuation Gap
Swedish private equity firm EQT is the sole potential buyer for nutraceutical ingredients maker OmniActive Health Technologies. This comes after a competing offer from a group including Temasek and Novo Holdings was reportedly rejected. EQT now holds a strong negotiating position. However, the deal faces a significant valuation gap. Initial expectations for OmniActive were around $1 billion, but the rejected consortium valued the company between $660 million and $700 million. This large gap suggests OmniActive's value may be lower than previously anticipated, potentially allowing EQT to negotiate at a discount.
Nutraceutical Market Growth vs. OmniActive's Price
The global nutraceutical market, which includes vitamins and supplements, is projected to grow from $105.15 billion in 2024 to $136.13 billion by 2029. India's market holds a significant share. Historically, mergers and acquisitions in the vitamin and supplement sector have seen average purchase multiples of around 11.2 times EBITDA. OmniActive reported revenues of about $98.6 million in FY25. Despite this industry growth, the current valuation disconnect for OmniActive points to specific challenges dampening buyer interest.
U.S. Trade Rules and FDA Scrutiny Dampen Value
A key reason for the lower valuation of OmniActive is its substantial export business to the United States. The U.S. Food and Drug Administration (FDA) and Federal Trade Commission (FTC) oversee dietary supplements, requiring strict adherence to labeling, advertising, and manufacturing standards. Recent changes, such as the end of the $800 de minimis exemption for imported goods, can lead to increased duties and inspection delays. Potential trade disputes, or "tariff wars," also create uncertainty. These evolving trade and regulatory dynamics present compliance challenges and risks for OmniActive's future revenue streams and operational stability.
TA Associates' Ownership and Previous Valuation
OmniActive Health Technologies was founded by Sanjaya Mariwala. It is currently majority-owned by U.S. private equity firm TA Associates, which acquired about 60% of the company in January 2021 for roughly $150 million. That stake sale valued the company at approximately $250 million, significantly less than current expectations. While EQT is the only bidder now, sources indicate TA Associates might restart the sale process if talks with EQT do not result in agreeable terms.
Deal Outlook Remains Uncertain
Negotiations between EQT and TA Associates are ongoing. The future of the deal remains uncertain, with EQT possibly securing OmniActive at a revised valuation or TA Associates seeking other buyers. The outcome will depend on EQT's assessment of the risks and TA Associates' willingness to adjust its price expectations.